New Characteristics of Anti-Factor VIII Inhibitor Antibody Epitopes and Unusual Immune Responses to Factor VIII

ABSTRACT

Treatment of individuals with severe hemophilia A by plasma-derived or recombinant factor VIII leads to the production of anti-factor VIII antibodies in approximately 30% of such patients. Because some of these antibodies inactivate factor VIII, they are considered a major factor in preventing optimal therapeutic treatment. Factor VIII is a cofactor that must bind to factors IX and X and phospholipids in order for normal blood coagulation to occur. The inhibition of factor VIII activity is due to binding by anti- factor VIII antibodies in the patient plasma to the same sites required for factors IX and X and phospholipid binding. Previously, inhibitor epitopes were localized to the A2, A3, and C2 domains and to a region of acidic amino acids between the A1 and A2 domains. Inhibitor binding to these domains prevented factor VIII binding to factor IXa (A2, A3), factor Xa (C2), and phospholipids (C2), and binding to the acidic region interfered with factor X binding. Antibody binding to a minor C2 domain epitope slowed activated factor VIII release from von Willebrand factor (vWF) and interfered with factor Xa binding to factor VIII.

KEYWORDS

Factor VIII - inhibitor antibody - inhibitor epitope - immune response

REFERENCES

• 1 Ahmad S S, Rawala-Sheikh R, Walsh P N. Components and assembly of the factor X activating complex.  Semin Thromb Hemost . 1992;  18 311-323
• 2 Rosing J, van Rijn J M L L, Bevers E M. The role of activated human platelets in prothrombin and factor X activation.  Blood . 1985;  65 319-332
• 3 Vehar G A, Keyt B, Eaton D. Structure of human factor VIII.  Nature . 1984;  312 337-342
• 4 Toole J J, Knopf J L, Wozney J M. Molecular cloning of a cDNA encoding human antihaemophilic factor.  Nature . 1984;  312 342-347
• 5 Zhong D, Saenko E L, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX.  Blood . 1998;  92 136-142
• 6 Fijnvandraat K, Celie P HN, Turenhout E AM. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain.  Blood . 1998;  91 2347-2352
• 7 Shima M, Nakai H, Scandella D. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.  Br J Haematol . 1995;  91 714-721
• 8 Saenko E L, Shima M, Gilbert G E, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.  J Biol Chem . 1996;  271 27424-27431
• 9 Healey J F, Lubin I M, Scandella D, Lollar P. Residues 484-509 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.  J Biol Chem . 1994;  270 14505-14509
• 10 Lenting P J, van de Loo H P J-W, Donath M-JSH, van Mourik A J, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.  J Biol Chem . 1996;  271 1935-1940
• 11 Saenko E L, Shima M, Rajalakshmi K J, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor.  J Biol Chem . 1994;  269 11601-11605
• 12 Foster P A, Fulcher C A, Houghten R A, de Graaf Mahoney S, Zimmerman T S. A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain.  Blood Coagul Fibrinolysis . 1990;  9 9-15
• 13 Foster P A, Fulcher C A, Houghten R A, de Graaf Mahoney S, Zimmerman T S. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine³⁵¹-serine³⁶⁵ of the factor VIII heavy chain.  J Clin Invest . 1988;  82 123-128
• 14 Lapan K, Fay P J. Localization of a factor X interactive site in the A1 subunit of factor VIIIa.  J Biol Chem . 1997;  272 2082-2088
• 15 Pipe S W, Kaufman R J. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.  J Biol Chem . 1996;  271 26571-26576
• 16 Shima M, Scandella D, Yoshioka A. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.  Thromb Haemost . 1993;  69 240-246
• 17 Prescott R, Nakai H, Saenko E L. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies.  Blood . 1997;  89 3663-3671
• 18 Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2.  Blood . 1993;  82 1767-1775
• 19 Thompson A R, Murphy M EP, Liu M L. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg⁵⁹³ to Cys mutation.  Blood . 1997;  90 1902-1910
• 20 Nogami K, Shima M, Hosokawa K. The role of FVIII C2 domain in factor VIII binding to factor Xa.  J Biol Chem . 1999;  274 31000-31007
• 21 Healey J F, Barrow R T, Tamim H M. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.  Blood . 1998;  92 3701-3709
• 22 Scandella D, Gilbert G E, Shima M. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248-2312 which overlap a phospholipid binding site.  Blood . 1995;  86 1811-1819
• 23 Pratt K P, Shen B W, Takeshima K. Structure of the C2 domain of human factor VIII at 1.5 Å resolution.  Nature . 1999;  402 439-442
• 24 Saenko E L, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.  J Biol Chem . 1995;  270 13826-13833
• 25 Nogami K, Shima M, Nakai H. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: Requirement of Cys2326 and Glu2327 for maximum effect.  Br J Haematol . 1999;  107 196-203
• 26 Fay P J, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa.  J Biol Chem . 1998;  273 19049-19054
• 27 Fay P J, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between A2 subunit and factor IXa.  J Biol Chem . 1999;  274 29826-29830
• 28 Lubin I M, Healey J F, Barrow R T, Scandella D, Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.  J Biol Chem . 1997;  272 30191-30195
• 29 Sawamoto Y, Prescott R, Zhong D. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.  Thromb Haemost . 1998;  79 62-68
• 30 Laub R, Di Giambattista M, Fondu P. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.  Thromb Haemost . 1999;  81 39-44
• 31 van den Brink N E, Timmermans S MH, Turenhout E AM. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg²⁹³ Cys substitution.  Thromb Haemost . 1999;  81 723-726
• 32 Peerlinck K, Jacquemin M, Arnout J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.  Blood . 1999;  93 2267-2273
• 33 Gilles J GG, Lavend'homme R, Peerlinck K. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.  Thromb Haemost . 1999;  82 40-45